Truist Securities Upgrades Biogen (BIIB) to Buy
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $207.22 +0.46%
Rating Summary:
27 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 33 | Down: 45 | New: 4
Rating Summary:
27 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 33 | Down: 45 | New: 4
Join SI Premium – FREE
Truist Securities analyst Danielle Brill upgraded Biogen (NASDAQ: BIIB) from Hold to Buy with a price target of $235.00.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $199.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ford Plans New Four-door Version Of Mustang - WSJ
- Keefe, Bruyette & Woods Upgrades TCP Capital (TCPC) to Market Perform
- BofA: US payrolls fell 23k in July, unemployment drops to 4.1%
Create E-mail Alert Related Categories
UpgradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
